Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease

Circulation

Volumn 115, Issue 18, 2007, Pages 2398-2409

  Chan, Paul S ^a,b   Nallamothu, Brahmajee K ^a,b   Gurm, Hitinder S ^a   Hayward, Rodney A ^a,b   Vijan, Sandeep ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholesterol; Coronary disease; Cost benefit analysis; Drugs; Statins

Indexed keywords

ATORVASTATIN; SIMVASTATIN; STATIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; LIFESPAN; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PRICING; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; REVASCULARIZATION; STROKE;

ACUTE DISEASE; ANGINA, UNSTABLE; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; COMORBIDITY; COMPUTER SIMULATION; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MARKOV CHAINS; MIDDLE AGED; MODELS, CARDIOVASCULAR; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; QUALITY-ADJUSTED LIFE YEARS; RISK; SYNDROME;

EID: 34248196018     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.667683     Document Type: Article

References (39)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
2. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
4. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
5. Lauer MS, Topol EJ. Clinical trials: multiple treatments, multiple end points, and multiple lessons. JAMA. 2003;289:2575-2577.
6. Chan PS, Nallamothu BK, Hayward RA. High-dose statins and the IDEAL trial. JAMA. 2006;295:2477.
7. Brown BG. Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression. Circulation. 2006;113:1382-1384.
8. Riviere M, Wang S, Leclerc C, Fitzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ. 1997;156:991-997.
9. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132:769 -779.
10. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J. 2001;141:727-734.
11. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ. 1996;312:1443-1448.
12. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H; Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336.
13. Gold M, Siegel J, Russell L, Weinstein M. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
14. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30.
15. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
16. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2006;47:2513-2520.
17. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
18. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
19. National Vital Statistics Reports: United States Life Tables, 2002. Hyattsville, Md: National Center for Health Statistics, Centers for Disease Control and Prevention; 2002.
20. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
21. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, et al; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
22. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
23. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
24. Kuntz KM, Weinstein MC. Life expectancy biases in clinical decision modeling. Med Decis Making. 1995;15:158-169.
25. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
26. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
27. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
28. Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol. 2006;48:112-121.
29. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158:1669-1677.
30. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest. 1995;108(suppl):457S-470S.
31. Red Book. Montvale, NJ: Medical Economics; 2005.
32. Holloway RG, Witter DM Jr, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
33. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after first stroke: a population-based study. Neurology. 1996;46:861-869.
34. Matchar DB, Samsa GP. Secondary and Tertiary Prevention of Stroke: Patient Outcomes Research Team (PORT) Final Report: Phase 1. Rockville, Md: Agency for Healthcare Research and Quality; 2000. AHRQ publication 00-N0001.
35. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making. 1992;12:239-249.
36. Cronenwett JL, Birkmeyer JD, Nackman GB, Fillinger MF, Bech FR, Zwolak RM, Walsh DB. Cost-effectiveness of carotid endarterectomy in asymptomatic patients. J Vasc Surg. 1997;25:298-309.
37. Agency for Healthcare Research and Quality. HCUPnet, healthcare cost and utilization; 2004. Available at: http://hcup.ahrq.gov/HCUPnet.asp. Accessed January 14, 2006.
38. US Department of Labor Bureau of Labor Statistics. Consumer Price Index: all urban consumers. US Department of Labor Bureau of Labor Statistics; 2004. Available at: http://www.bls.gov.proxy.lib.umich.edu/data/. Accessed May 26, 2006.
39. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006;113:1406-1414.